Tucatanib Intermediates: Driving Innovation in HER2-Positive Cancer Treatment

Aug 5, 2025 · 3 min read · The pharmaceutical industry has witnessed remarkable advancements in targeted cancer therapies, particularly in treating HER2-positive breast cancer. One of the most promising drugs in this domain is Tucatanib, a tyrosine kinase inhibitor that specif...